Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma... see more

Current News (NDAQ:CASI)

CASI Pharmaceuticals Announces Changes in Board Governance

ACCESS Newswire November 19, 2025

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

ACCESS Newswire November 14, 2025

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

ACCESS Newswire November 10, 2025

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

ACCESS Newswire November 4, 2025

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

ACCESS Newswire November 3, 2025

CASI Pharmaceuticals Appoints James Huang to Board of Directors

ACCESS Newswire September 26, 2025

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

ACCESS Newswire September 8, 2025

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

ACCESS Newswire September 3, 2025

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

ACCESS Newswire September 2, 2025
View More News ››

Opinion & Analysis (NDAQ:CASI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CASI)

Using technical analysis for this stock.

It is starting a big uptrend for shareholders of this company today so good luck to all 
coolfooldumbguy - August 4, 2025

CASI Pharmaceuticals Faces Headwinds, but Promising Pipeline

http://beyondspx.com/2024/08/01/casi-pharmaceuticals-faces-headwinds-but-promising-pipeline-offers-hope/
MikeTester - August 1, 2024

I'm Out

Sold for some nice gains - going down
mpetit - June 6, 2009

I agree

Took are real dive and got in during year end sell off - lucky me
mpetit - May 18, 2009

Am I the only one holding

Not to much action here
mpetit - March 5, 2008

Entering on this downturn

Bidding 1.19 time will tell
mpetit - December 27, 2007
View more Bullboard ››

AJA Health and Wellness Inc

AJA Health and Wellness Inc

AJA Health and Wellness Inc. operates a telemedicine platform and full-service travel clinics. The company offers virtual ...
View More »